Atypical Hippo signaling network: uncovering novel insights into head and neck cancer biology and advancements in precision intervention
- PMID: 40486910
- PMCID: PMC12141295
- DOI: 10.3389/fcell.2025.1610471
Atypical Hippo signaling network: uncovering novel insights into head and neck cancer biology and advancements in precision intervention
Abstract
As a major global health challenge with rising incidence and poor prognosis, head and continues to impose a significant clinical burden due to its aggressive biological behavior and frequent therapeutic resistance. Within this context, the atypical Hippo signaling pathway emerges as a crucial regulatory network, integrating diverse components including core kinases (TAO kinases, MAP4K family, NDR1/2 kinases), cell polarity determinants (CRUMBS, SCRIBBLE), junctional adhesion molecules (AMOT family), phosphorylation mediators (14-3-3 proteins), and tumor suppressors (NF2, RASSF family). This multifaceted system governs fundamental cellular processes spanning proliferation, apoptosis, migratory capacity, and immune microenvironment modulation. Notably, post-translational modifications (ubiquitination, acetylation, SUMOylation) of pathway components dynamically regulate the stability and activity of downstream effectors YAP/TAZ, whose sustained activation through molecular aberrations drives tumor progression and treatment resistance in head and neck malignancies.The pathway's extensive crosstalk with Wnt signaling, NF-κB cascades, and estrogen receptor networks creates context-dependent regulatory plasticity that contributes to tumor heterogeneity. Current therapeutic innovation focuses on molecular diagnostics and precision targeting approaches, including direct YAP/TAZ-TEAD complex inhibitors, upstream receptor modulators, and rational combinations with immune checkpoint blockade. Future investigations should employ multi-omics profiling to delineate tumor subtype-specific regulatory architectures while advancing novel drug delivery platforms. These efforts promise to translate mechanistic insights into multi-targeted therapeutic strategies capable of overcoming resistance mechanisms and improving survival outcomes for this therapeutically challenging malignancy.
Keywords: PTM homeostasis; atypical Hippo signaling; head and neck cancer; kinase; multipathway crosstalk.
Copyright © 2025 Yang and Li.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Molecular mechanisms of Hippo pathway in tumorigenesis: therapeutic implications.Mol Biol Rep. 2025 Feb 27;52(1):267. doi: 10.1007/s11033-025-10372-y. Mol Biol Rep. 2025. PMID: 40014178 Review.
-
Targeting YAP/TAZ-TEAD signaling as a therapeutic approach in head and neck squamous cell carcinoma.Cancer Lett. 2025 Mar 1;612:217467. doi: 10.1016/j.canlet.2025.217467. Epub 2025 Jan 16. Cancer Lett. 2025. PMID: 39826667
-
A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.Mol Cancer Ther. 2024 Jan 3;23(1):3-13. doi: 10.1158/1535-7163.MCT-22-0681. Mol Cancer Ther. 2024. PMID: 37748190
-
The Hippo Pathway Effectors YAP/TAZ-TEAD Oncoproteins as Emerging Therapeutic Targets in the Tumor Microenvironment.Cancers (Basel). 2023 Jul 2;15(13):3468. doi: 10.3390/cancers15133468. Cancers (Basel). 2023. PMID: 37444578 Free PMC article. Review.
-
Establishment of transgenic lines to monitor and manipulate Yap/Taz-Tead activity in zebrafish reveals both evolutionarily conserved and divergent functions of the Hippo pathway.Mech Dev. 2014 Aug;133:177-88. doi: 10.1016/j.mod.2014.02.003. Epub 2014 Feb 19. Mech Dev. 2014. PMID: 24560909 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous